Atrial Fibrillation

Results of a new study suggest that number of LAA lobes may one day be useful as an element of the CHADS2 scoring system for embolic risk in patients with atrial fibrillation.

Comprising 15,400 patients from 46 countries, the RE-LY AF registry offers a notable opportunity to study variations in presentation of atrial fibrillation and its risk factors.

In dialysis patients, anticoagulation for AF may be cause for clinical equipoise, regardless of bleeding risk score. New research, reported here, may begin to shift the balance.

An observational study of patients with atrial fibrillation suggests that routine screening for depression at office visits may help augment treatment.

A new study provides more evidence of important bidirectional relationships between AF and other cardiovascular comorbidities.

Risk factor control is essential to reduce the symptom burden and severity of atrial fibrillation. A new study finds that weight loss is a highly effective tool in an overall mitigation strategy.

A new study finds a lower incidence of AF in non-White races even though these groups have a higher risk of comorbidites that predispose to AF.

Andexanet alfa is a recombinant factor Xa molecule that binds to and sequesters factor Xa inhibitors in the blood, making them unavailable to bind to native factor Xa.

In new-onset atrial fibrillation there is good evidence for obtaining a troponin T level. High levels are associated with highest rates of stroke, embolism, and cardiac mortality.

Dabigatran was shown in post-hoc analysis of the RE-LY trial to be associated with an increased risk of MI compared with warfarin.

Rivaroxaban when used to treat patients with atrial fibrillation who have had a previous MI is associated with higher risk for adverse events.

Whether to prescribe an antiplatelet or antithrombotic agent for a patient who has AF but is otherwise healthy can be a difficult decision.

Cardioversion for paroxysmal atrial fibrillation must include pre- and post-procedure anticoagulation to avoid thromboembolic risk.

Only one agent can be used for anticoagulation in individuals with mechanical valves.

Vitamin D supplementation in the VitDISH study did not improve isolated systolic hypertension in elderly patients who were deficient.

Researchers saw significant results, including a 56% reduction in overall apnea events per hour and a more than 80% reduction in CSA events.

Aldosterone has significant effects on vascular function and can decrease flow-mediated vasodilation.

Persons with type 2 diabetes are at risk for asymptomatic atrial fibrillation and subsequent cerebrovascular events.

Undiagnosed AF was discovered in 3% of individuals; 2% of individuals with known AF who were not on oral anticoagulation were also identified.

Pulmonary vein ablation has not gained recognition as a "cure" for atrial fibrillation so a new approach would be welcomed.

Patients with mechanical heart valves are not candidates for dabigatran; excess bleeding curtailed the first study to test it.

Reassess rate vs rhythym control, appropriate anticoagulation therapy and potential drug-drug interactions.

Smoking can increase cholesterol, triglycerides, and LDL while decreasing HDL.

Bleeding risk is increased in patients receiving oral anticoagulation and concomitant aspirin.

This agent has a large number of drug-drug and drug-food interactions, and there is a need for increased INR monitoring.

Oral apixaban for acute VTE was superior to enoxaparin followed by warfarin.

Syncope accompanied by a sensation of coldness preceded a fall in this 67-year-old woman. She had a similar experience 6 months earlier.

Pulmonary embolism was the diagnosis in these 3 women, each of whom presented with positional right flank pain.

Novel anticoagulants have a half life much shorter than warfarin and so adherence and medication error are significant issues.